echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > The new stem cell therapy is expected to cure leukemia completely

    The new stem cell therapy is expected to cure leukemia completely

    • Last Update: 2021-02-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    Stem cell transplants can be effective in treating leukemia, but in many cases, immune cells from the receptor attack the healthy tissue of the recipient's body, with lethal consequences, and in a recent study published in the international journal Science Translational Medicine, scientists from the University of Zurich and others identified a special molecule that plays a key role in the process, blocking the molecule's function and significantly improving the prognostic status of patients receiving stem cell transplant therapy.
    Stem cell therapy offers hope for a full recovery for patients with leukemia or bone marrow cancer, which requires removing cells affected by chemotherapy or radiotherapy and then replacing them with blood stem cells from healthy donor bodies that can produce new blood cells and attack cancerous cells in the patient's body, thereby suppressing the recurrence of cancer.Responsive response
    However, the treatment is not risk-free, and in 30 to 60 percent of cases, cells from the receptor often attack the healthy tissue of the receptor, especially the liver, intestinal tissue, and skin tissue; The therapy has limitations or disadvantages, but it can also reduce the anti-cancer effect of the supply cells on the patient's body cancer cells, so there is an urgent need for researchers to understand how to reduce the anti-host response of the graft without reducing the anti-cancer effect of transplanted theCytokines
    study, researchers found that the production of cytokines called GM-CSF, which is produced by a special class of white blood cells, can help ward off infections in healthy people in the pathology of the graft's anti-host pathology. In the article, the researchers used mouse models to study that these transplanted cells produced a large number of GM-CSF factors during the transplant anti-host response, and that if the mouse body was injected with a supply cell that could not produce GM-CSF, the mice would be exempt from a lethal response, so targeting the cytokines could produce a precise, specific immunosuppressive effect, which may hopefully block tissue damage caused by the transplant's resistance to host reactions.
    Initially, researchers were concerned that the mediator GM-CSF factor would reduce the anti-cancer effects of the cells of the supply, but after a later in-depth study they found that this might not be the case; researcher Sonia Tugues said the actual results surprised us that we thought all types of immune responses were mediated by the same mechanism, and now we have found a way to separate the desired process from the desired process from the cells of the supply.Translation of mouse body results into human clinical trials
    the researchers then wanted to clarify whether GM-CSF factors played the same key role in the human body and in mouse bodies, and after analyzing tissue from the receptor anti-host response in the patient's body, the researchers found that this was true, with higher levels of GM-CSF in the patient's transplant-resistant GM-CSF, and higher levels in affected tissues.
    Now researchers hope to conduct clinical trials to test whether blocking the function of GM-CSF factor inhibits the anti-host response of transplants in recipient patients after stem cell transplantation; If the anti-cancer effect can be preserved while blocking the anti-host response of the graft, the process may succeed in improving the patient's prognostication and bringing smaller side effects, a therapeutic strategy that may hopefully help improve the health of patients with poor prognostication or at risk of death, he said.
    original source: Sonia Tugues 1, Ana Amorim1, Sabine Spath, et al. Graft-versus-host disease, but not graft-versus-leukemia immunity, is mediated by GM-CSF–licensed myeloid cells, Science Translational Medicine 28 Nov 2018,Vol. 10, Issue 469, eaat8410 DOI: 10.1126/scitranslmed.aat8410 (Bio Valley)
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.